eligibility_summary
Eligibility: Adults ≥18 with RRMM after ≥3 lines (incl PI+IMiD), measurable disease, BCMA+, transplant‑ineligible/relapsed, prior CAR‑T allowed if ≥3 mo and undetectable, ECOG 0–1, ≥12‑wk survival, adequate hematologic, hepatic, renal, coagulation, pulmonary (SpO2>92%) and cardiac (LVEF≥50%) function. Exclude: chronic immunosuppression, recent stroke/seizure, other cancers, active viral/STI, serious heart/organ disease, neuro disorder, unresolved AEs, infection, pregnancy plans, or per investigator.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: UTAA17 Injection—a biological, gene‑modified cell therapy of γδ T cells engineered with a BCMA‑targeted chimeric antigen receptor (CAR). Single infusion after pretreatment, dose levels: 3×10^8, 5×10^8, 1×10^9, 5×10^9, or 1×10^10 CAR+ γδ T cells. Mechanism of action: CAR recognition of BCMA (TNFRSF17) on myeloma cells activates γδ T cells to proliferate and kill tumor cells via MHC‑independent cytotoxicity (e.g., perforin/granzyme and cytokine release), aiming to clear BCMA+ malignant plasma cells. Cells/pathways targeted: BCMA‑expressing plasma cells in relapsed/refractory multiple myeloma, BCMA signaling axis, immune effector functions of γδ T cells. Efficacy assessed per IMWG criteria, study focuses on safety, pharmacokinetics, immunogenicity, and recommended dose.